Treatment of viral infection

Abstract

The invention is directed to the treatment of COVID-19 patients by administering to patients either infected by SARS-CoV-2 or presymptomatic for COVID-19 but at risk of severe morbidity and mortality due to potential COVID-19 infection. Such patients are given modified pectin, preferably modified citrus pectin, in an amount that may range from 2.5 or 5 on up to 10-25 grams per day, divided into two or three doses per day. The administration may be oral, by inhalation, intrabuccal or IV. The process may be combined with the administration of supportive agents like antivirals, anti-inflammatories, immune based inhibitors, vitamins, monoclonal and polyclonal anti-viral or viral binding antibodies.

Description

PRIORITY DATA AND INCORPORATION BY REFERENCE

[0001] This application is related to, but does not claim priority from, U.S. Pat. Nos. 8,764,695; and 10,213,462; U.S. patent application Ser. No. 15 / 081,958 (allowed) and U.S. patent application Ser. No. 15 / 104,302. Each of these U.S. Patents and applications are incorporated herein-by-reference. Taken together, these patents clearly establish the efficacy of plasmapheresis to reduce the level in a mammal such as a human the level an agent that binds to a target also bound by circulating galectin-3 (gal-3 herein). This application is related to and claims priority from U.S. patent application Ser. No. 17 / 017,502 filed Sep. 10, 2020. The latter is directed principally to the treatment of SAR-CoV-2 infection by apheresis.BACKGROUND OF THE INVENTIONField of the Invention

[0002] This invention pertains to treatment of viral infections, which may include infections from MERS, SARS, SARS-CoV-2, INFLUENZA, MEASLES, HSV I&II, HPV and other opportun...